IL-6R Protein

IL-6R Protein

Pathway Diagram

```mermaid
flowchart TD
IL10["IL-10<br/>Anti-inflammatory<br/>Cytokine"]
ROS_gene["ROS<br/>Reactive Oxygen<br/>Species"]
RIPK1["RIPK1<br/>Cell Death<br/>Regulator"]
STAT3["STAT3<br/>Transcription<br/>Factor"]

Interleukin["Interleukin<br/>Pro/Anti-inflammatory<br/>Cytokines"]

PPARG["PPARG<br/>Metabolic<br/>Regulator"]
TFEB["TFEB<br/>Autophagy<br/>Master Regulator"]
HSP70["HSP70<br/>Heat Shock<br/>Protein"]
AMPK["AMPK<br/>Energy Sensor"]

Neuroinflammation["Neuroinflammation<br/>Microglial Activation"]
Fibrosis["Fibrosis<br/>Tissue Scarring"]
ALS["ALS<br/>Motor Neuron<br/>Disease"]

Cell_Death["Cell Death<br/>Neuronal Loss"]
Neuroprotection["Neuroprotection<br/>Survival Pathways"]

IL10 -->|"activates"| Interleukin
ROS_gene -->|"regulates"| Interleukin
RIPK1 -->|"interacts_with"| Interleukin
STAT3 -->|"interacts_with"| Interleukin

Interleukin -->|"promotes"| Neuroinflammation
Interleukin -->|"regulates"| Fibrosis
Interleukin -->|"therapeutic_target"| ALS

PPARG -->|"interacts_with"| Interleukin
TFEB -->|"interacts_with"| Interleukin
HSP70 -->|"interacts_with"| Interleukin
AMPK -->|"interacts_with"| Interleukin

Neuroinflammation -->|"leads_to"| Cell_Death
HSP70 -->|"promotes"| Neuroprotection
TFEB -->|"promotes"| Neuroprotection

style Interleukin fill:#006494
style IL10 fill:#1b5e20
style HSP70 fill:#1b5e20
style TFEB fill:#1b5e20
style AMPK fill:#1b5e20
style PPARG

IL-6R Protein

Pathway Diagram

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">IL-6R Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Interleukin-6 Receptor</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[IL6R](/genes/il6r)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P08887](https://www.uniprot.org/uniprot/P08887)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~80 kDa (membrane-bound), ~55 kDa (soluble)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cell membrane, Golgi apparatus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>IL-6 receptor family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Rheumatoid Arthritis</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Tocilizumab</td>
<td>Humanized anti-IL-6R antibody</td>
</tr>
<tr>
<td class="label">Sarilumab</td>
<td>Fully human anti-IL-6R antibody</td>
</tr>
<tr>
<td class="label">Siltuximab</td>
<td>Anti-IL-6 chimeric antibody</td>
</tr>
</table>
title: IL-6R Protein
:: infobox .infobox-protein
::

Interleukin-6 Receptor (IL-6R)

Introduction

The Interleukin-6 Receptor (IL-6R) is a critical cytokine receptor that plays a significant role in neuroinflammation, a key pathological feature of neurodegenerative diseases including Alzheimer's Disease (AD) and Parkinson's Disease (PD)[@ilr2023]. IL-6R mediates the cellular response to interleukin-6 (IL-6), a pleiotropic cytokine that participates in both acute phase responses and chronic inflammatory processes[@interleukin2022]. The IL-6R signaling pathway has become an important therapeutic target, with tocilizumab (an IL-6R antagonist) showing promise in clinical trials for various neurological conditions[@tocilizumab2023].

Overview

Interleukin-6 Receptor (IL-6R) is a transmembrane protein encoded by the IL6R gene on chromosome 1q21.3[@ilr2021]. It exists in two forms: a membrane-bound receptor (mIL-6R) of approximately 80 kDa and a soluble receptor (sIL-6R) generated by proteolytic cleavage or alternative splicing[@soluble2022]. The membrane-bound IL-6R is expressed on various cell types including hepatocytes, leukocytes, and certain neuronal populations, while the soluble form can bind IL-6 and trigger signaling in cells that express the signal-transducing subunit gp130 but lack IL-6R itself—a phenomenon known as trans-signaling[@transsignaling2021].

The IL-6R pathway is particularly relevant to neurodegeneration because chronic neuroinflammation is a hallmark of both AD and PD[@neuroinflammation2023]. Elevated levels of IL-6 and sIL-6R have been detected in the cerebrospinal fluid (CSF) and post-mortem brain tissue of patients with AD and PD, suggesting that dysregulated IL-6 signaling contributes to disease progression[@csf2022]. Genetic studies have also identified IL6R variants as risk factors for AD, further supporting its pathogenic role[@ilr2021a].

Structure

Extracellular Domain

The IL-6R extracellular domain consists of three distinct regions[@crystal2020]:

Transmembrane and Cytoplasmic Domains

• Transmembrane helix: Single 28-amino acid hydrophobic segment anchors the receptor
• Cytoplasmic tail: Short 82-amino acid domain lacks intrinsic kinase activity but recruits signaling proteins

Soluble IL-6R (sIL-6R)

The soluble form (~55 kDa) retains the extracellular domain and can[@adammediated2022]:

• Bind IL-6 with similar affinity as membrane-bound receptor
• Form a complex with IL-6 that activates gp130-expressing cells
• Be generated by ADAM17-mediated proteolytic shedding (ectodomain shedding)

Normal Physiological Functions

Acute Phase Response

IL-6R signaling is essential for hepatic acute phase protein synthesis[@acute2021]:

• Stimulates production of C-reactive protein (CRP)
• Induces fibrinogen and serum amyloid A
• Regulates body temperature through hypothalamic-pituitary-adrenal axis

Immune Regulation

The IL-6R pathway modulates adaptive and innate immunity[@ilr2023a]:

• B cell differentiation: Promotes plasma cell formation and antibody production
• T cell polarization: Drives Th17 differentiation while inhibiting Treg cells
• Monocyte/macrophage function: Modulates cytokine production and phagocytosis

Neuronal Function

In the central nervous system, IL-6R signaling affects[@cns2022]:

• Neurogenesis: Regulates neural progenitor cell proliferation and differentiation
• Synaptic plasticity: Modulates [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and memory formation
• Astrocyte function: Influences astrocyte reactivity and scar formation

Role in Neurodegenerative Diseases

Alzheimer's Disease

IL-6R signaling contributes to AD pathogenesis through multiple mechanisms[@ilr2023b]:

Elevated sIL-6R in CSF correlates with cognitive decline in AD patients, making it a potential biomarker[@soluble2022a].

Parkinson's Disease

In PD, IL-6R signaling promotes dopaminergic neuron degeneration[@ilr2023c]:

• Neuroinflammation: Sustained IL-6 signaling activates [microglia](/cell-types/microglia-neuroinflammation) in the substantia nigra
• Oxidative stress: Increases [ROS](/entities/reactive-oxygen-species) production in dopaminergic [neurons](/entities/neurons)
• [α-Synuclein](/proteins/alpha-synuclein) pathology: May accelerate α-synuclein aggregation
• [Blood-brain barrier](/entities/blood-brain-barrier) (BBB) disruption: Compromises BBB integrity

Other Neurodegenerative Conditions

IL-6R dysregulation is also implicated in[@ilr2022]:

• Multiple Sclerosis (MS): Promotes demyelination and lesion formation
• Amyotrophic Lateral Sclerosis (ALS): Accelerates motor neuron death
• Frontotemporal Dementia (FTD): Contributes to neuroinflammation

Therapeutic Targeting

IL-6R Antagonists

Several therapeutic agents target IL-6R signaling[@ilr2023d]:

Clinical Trials

Recent and ongoing trials target IL-6R in neurodegeneration[@clinical2024]:

• TOCIVAS trial: Tocilizumab in AD (completed, mixed results)
• Parkinson's studies: IL-6R blockade showing promise in early trials
• Multiple sclerosis: Natalizumab (anti-α4-integrin) combined with IL-6R modulation

See Also

• [Interleukin-6 (IL-6) Signaling in Neurodegeneration](/mechanisms/il6-signaling-neurodegeneration)
• [Neuroinflammation and Microglia Pathway](/neuroinflammation-and-microglia-pathway)
• [Cytokine Networks in Neurodegeneration](/mechanisms/cytokine-networks)
• [Alzheimer's Disease Pathogenesis](/diseases/alzheimers-disease)
• [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)

Background

The study of Il 6R Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References